CV Therapeutics touts heart-imaging drug's Phase III data

Palo Alto, California-based CV Therapeutics announced that its heart-imaging drug met the primary endpoint in a Phase III pivotal trial. Regadenoson is intended to increase blood flow and dilate coronary arteries so that a scan will reveal any threatening blockages and restrictions. Many patients increase their blood flow for the procedure with exercise, but a large group are physically incapable of doing it. The trial compared Regadenoson to Adenoscan from Astellas, which is partnered with CV on developing Regadenoson. A second Phase III trial is currently underway.

- read this story from the San Francisco Business Times for more

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.